A Safety and Efficacy Study of a New Eye Drop Formulation in Patients With Dry Eye Disease.

A Multicenter, Double-masked, Randomized Study to Compare the Safety and Efficacy of the OM3 Tear Formulation With REFRESH OPTIVE® ADVANCED Unit Dose for 3 Months in Patients With Dry Eye Disease

This study will evaluate the safety and efficacy of a new eye drop formulation in patients with dry eye disease.

Inclusion Criteria:

• Used artificial tears for dry eye
• Visual acuity of at least 20/32 (while wearing glasses, if necessary).

Exclusion Criteria:

• Use of contact lenses in the last 3 months, or anticipated use of contact lenses during the study
• Herpes keratitis in the last 6 months
• Cataract surgery, laser-assisted in situ keratomileusis [LASIK], or photorefractive keratectomy, within the last 6 months